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ABSTRACT 
 
 
Foster, Micah John. The Difference In Physiological Parameters Following An Exercise  
Intervention In Breast Cancer Survivors On A Single Chemotherapy Drug Versus 
Combination Chemotherapy Drugs. Published Master of Science thesis, 
University of Northern Colorado, 2010.  
 
 Exercise has become an important part of cancer rehabilitation as the incidence of 
breast cancer is increasing and the mortality rate is decreasing.  Breast cancer 
chemotherapy treatment induces a physical demand on the body while exercise counter 
balances symptoms of chemotherapy treatment.  The purpose of this investigation was to 
determine the effects an exercise intervention has on breast cancer survivors who have 
received a single chemotherapy drug versus combination chemotherapy drugs.  A 
secondary purpose was to determine any differences in chemotherapy categories. 
Participants were chosen that had single drug treatment (n = 34) and combination drug 
treatment (n = 20).  Groups completed a pre-physiological assessment followed by an 
exercise intervention.  Following the exercise intervention, a post-assessment was 
obtained.  The protocol for all assessments was the same for all breast cancer survivors, 
but each exercise intervention was individualized.  Within single and combination 
chemotherapy groups pre- to post-assessment, results showed significant improvement 
(P<0.05) in pulmonary function [FVC% - Single – change (2.04%) and Combination – 
change (5.66%)] and [FEV1% - Single – change (3.87%) and Combination – change 
(6.60%)], chest press [Single – change (6.50%) and Combination – change (6.50%)], lat 
pulldown [Single – change (9.70%) and Combination – change (6.90%)], shoulder press 
[Single – change (9.20%) and Combination – change (9.75%)], and sit-and-reach [Single 
– change (0.40%) and Combination – change (0.55%)].  Resting heart rate was 
significantly (P<0.05) improved only in the combination group – change (-6.60%).  The 
data suggest that exercise is beneficial for breast cancer survivors whether on a single 
chemotherapy drug or on a combination of multiple chemotherapy drugs.  Additionally, 
no significant differences were found between chemotherapy categories or the interaction 
between therapy and drug categories. 
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CHAPTER I 
 
 
INTRODUCTION 
 
Breast cancer is the most common cancer among women, accounting for roughly 
1 in 4 cancers diagnosed in women in the United States, with the exception of skin 
cancer.  (Breast Cancer Facts & Figures, 2009-1010)  Since 1990, women in the United 
States under the age of 50 have shown a drop in death rates of 3.2% per year and those 50 
and older have shown a drop of 2% per year. (Cancer Facts and Figures, 2010) In 
addition, from 1999-2005, the incidence of female breast cancer has declined 2.2% per 
year, after incessantly increasing for over two decades.  (Cancer Facts & Figures, 2010)  
Risk factors include age, gender, family history, postmenopausal obesity, alcohol 
consumption, physically inactive, and the use of combined estrogen and progestin 
menopausal hormones.  (Breast Cancer Facts & Figures, 2009-2010)   
Chemotherapy treatments with single-agent, sequential single-agent, and 
combination chemotherapy regimens have had a significant physiological and 
psychological impact on breast cancer survivors.  In a review by Cardoso, Bedard, Winer, 
Pagani, Senkus-Konefka, Fallowfield, et al. (2009), it was suggested that there is an 
improvement in overall survival rate (P<0.001) with combination versus single-agent 
chemotherapy in metastatic breast cancer. Francis, Crown, Di Leo, Buyse, Balil, 
Andersson, et al. (2008) found that the use of sequential chemotherapy treatment was 
better in disease-free survival compared to concurrent chemotherapy treatment.  Carlson 
& Telli, (2009) suggested that while combination chemotherapy is associated with greater 
toxicity than with sequential chemotherapy, sequential chemotherapy is the preferred 
approach for most patients. Mauri, Polyzos, Salanti, Pavlidis, and Ioanndis (2008) found 
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that anthracycline regimens compared with single-agent chemotherapy with 
nonanthracycline drugs had a 22-33% relative risk reduction in mortality. Jones (2008) 
suggested superior survival outcomes with taxane-based regimens, nonanthracyclines, 
and trastuzumab. In a study by Miles, von Minckwitz, and Seidman (2002), combination 
versus sequential chemotherapy was found to show significant (P<0.05) improvement in 
response rate, median time to progression, and median overall survival.  However, there 
has not been enough evidence to establish a universal consensus on which chemotherapy 
treatment regimen is the most effective. 
Exercise interventions used in cancer rehabilitation settings have had a 
physiological impact on breast cancer survivors.  In a review by Spence, Heesch, and 
Brown (2009), improvements were found in physical performance (P<0.05) and walking 
(P<0.01). Vallance, Plotnikoff, Karvinen, Mackey, and Courneya (2010) found that 
breast cancer survivors who met the physical activity guidelines at baseline (P<0.001) 
and post intervention (P<0.001), had a greater likelihood of meeting the physical activity 
guidelines at 6 months follow-up. Sprod, Hsieh, Hayward, and Schneider (2010) found 
significant (P<0.05) improvements in cardiovascular endurance in breast cancer survivors 
undergoing 3- and 6-month individualized exercise interventions.  Additional 
improvements (P<0.05) were shown for breast cancer survivors exercising for 6-months 
in pulmonary function and muscular endurance.  
Exercise has also been found to reduce many of the psychological side effects 
associated with breast cancer. Blanchard, Courneya, and Laing (2001) found that acute 
exercise was an effective intervention in reducing (P<0.03) the state anxiety in breast 
cancer survivors.  Brown et al. (2009) found improvements in quality of life and fatigue, 
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while Vallance et al. (2010) found significant improvements in physical activity behavior 
(P<0.001), psychosocial functioning (P<0.001), and motivation (P<0.001), and Sprod et 
al. (2010) found significant (P<0.05) improvements in fatigue and symptoms of 
depression. 
The combination of chemotherapy and exercise treatment with breast cancer 
survivors has a significant impact on physiological and psychological parameters and 
side effects.  However, more information is needed regarding chemotherapy regimens, 
chemotherapy categories, and exercise to determine any significant effects on breast 
cancer.  Additionally it is necessary to establish whether one chemotherapy treatment 
regimen is better in regards to the outcomes of exercise assessments. 
Statement of Purpose 
 
 The purpose of this research was to determine the differences in physiological 
parameters following an exercise intervention in female breast cancer survivors on a 
single chemotherapy drug versus combination chemotherapy drugs.  A secondary 
purpose was to determine any differences in chemotherapy categories. 
Research Hypotheses 
H1:  The main hypothesis for this investigation was that breast cancer survivors 
receiving single-agent and sequential single-agent chemotherapy treatment would 
show significantly greater results in physiological parameters measured in pre- 
and post-exercise assessments compared to breast cancer survivors receiving 
combination chemotherapy.  
H2:  The chemotherapy categories will show significant differences in 
physiological parameters. 
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H3:  Exercise will enhance performance pre- to post-exercise intervention. 
Assumptions 
 
 This study was conducted under the assumption that participants did not engage in 
activities other than those exercises performed under the supervision of a cancer exercise 
rehabilitation specialist at the Rocky Mountain Cancer Rehabilitation Institute.   
Limitations 
 
There were several limitations with this study.  First, the breast cancer survivors 
weren’t all at the same stage of recovery.  The exercise intervention was individualized 
and therefore clients did not perform the same exercises. 
Significance of the Study 
 
 The relationship between single-agent, sequential single-agent, and combination 
chemotherapy treatment with female breast cancer survivors and overall survival, 
progression-free survival, disease-free survival, and time to treatment failure has been 
established (Biganzoli et al., 2002; Chan et al., 1999; Citron et al., 2003; Forbes et al., 
(2008); Henderson et al., 2003; Jones et al., 2006; Jones et al., 2005; Mamounas et al., 
2005; Marty et al., 2005; Miller et al., 2007; Nabholtz et al., 2003; Paridaens et al., 2000; 
Piccart-Gebhart et al., 2006; Robert et al., 2006; Seidman et al., 2008;  Slamon et al., 
2001; Sledge et al., 2003; Sparano et al., 2008).  The physiological benefits of an exercise 
intervention for female breast cancer survivors receiving chemotherapy treatment have 
also been established (Campbell et al., 2005; Courneya et al., 2003; Drouin et al., 2006; 
Hsieh et al., 2008; Kolden et al., 2002; Matthews et al., 2007; Mock et al., 2004; Mutrie 
et al., 2007; Nikander et al., 2007; Pinto et al., 2003; Schneider et al., 2007).   
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However, no research has been found that determines the physiological 
differences in response to single-agent, sequential single-agent, and combination 
chemotherapy treatment or determining if differences exist between categories of 
chemotherapy drugs.  Therefore, this study was designed to determine the physiological 
alterations that occur with exercise in breast cancer survivors who received varying 
regimens and categories of chemotherapy drugs. 
Definition of Terms 
 
 Adenocarcinoma (AC).  A cancer histotype that originates in glandular tissue –  
the part of an epithelial tissue which includes skin, glands, and other tissues that line the 
organ/body’s cavities. 
Adjuvant setting.  Additional treatment given after surgery. 
Apoptosis.  Digestion by phagocytes of cell fragments from destroyed cells. 
 Anaphase.  Third stage of mitosis in which a full set of daughter chromosomes 
move toward each pole of a cell. 
 Anaplasia.  A reversion of differentiation in cells and is characteristic of 
malignant tumors. 
Antineoplastics. Drugs that inhibit neoplasms. 
Arthralgias. Joint pain due to injury, infection, illnesses, or allergic reaction to  
medication. 
 Axillary lymph nodes.  Small oval-shaped organs of the immune system located 
in the armpit region of the body. 
Biopsy-confirmed hyperplasia. The increase of cells especially atypical 
hyperplasia. 
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Bone marrow.  Soft substance inside bones. 
Cachexia.  Weight loss. 
Cell proliferation.  Rapid cell reproduction. 
Chemotherapy.  Administration of cytotoxic chemicals to destroy malignant 
tumor cells. 
Comorbidity.  The appearance of multiple illnesses. 
Cytokinesis.  The division of cytoplasm that occurs after the cell nucleus has 
divided. 
DNA (deoxyribonucleic acid).  A nucleic acid found in all living cells; it carries 
the organism’s hereditary information. 
Drop Foot.  Deficiency in dorsiflexion of the ankle and toes. 
Dyspnea.  Shortness of breath. 
Filgrastim. A granulocyte colony-stimulating factor (G-CSF) analog used to 
stimulate the proliferation and differentiation of granulocytes. 
Forced Expiratory Volume (FEV1). Is the volume of air exhaled in the first 
second after maximal inhalation. 
Forced Vital Capacity (FVC).  The maximal amount of air a person can expel 
from the lungs after a maximum inspiration. 
Genome. Entirety of an organism’s heredity. 
Granulocytopenia.  Neutrophil deficiency that reduces fight against infection, 
basophils, and eosinophils.  
Hematopoietic. Blood cell component formation. 
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 High breast tissue density. A mammographic measure of the amount of glandular 
tissue relative to fatty tissue in the breast. 
 High bone mineral density. A routinely measured to identify women at increased 
risk for osteoporosis. 
 Hyperplasia.  An enlargement caused by increased cells. 
 Kinase.  An enzyme that transfers phosphate groups from high-energy donor 
molecules to specific substrates. 
 Leucopenia. Low white blood cell count. 
 Lymphatic system. Vessels transporting lymph. 
 Lymphedema.  Swelling of subcutaneous tissues caused by obstruction of 
lymphatic drainage. 
 Lymphocytes. Type of white blood cells. 
 Malignant tumor.  An invasive tumor that has the competence to form metastic 
colonies. 
 Mammogram. An x-ray of the breast. 
 Mastectomy.  Surgical breast cancer treatment involving the removal of the breast 
tissue while leaving the skin, nipple, pectoral muscles and lymph nodes. 
 Melanocytes.  Malignant pigment-producing cells. 
Metaphase.  Second stage of mitosis. 
 Metastasis.  The manifestation of a malignancy in a secondary growth in a new 
location arising from the primary growth. 
 Mitosis.  Process during which the chromosomes are redistributed to two daughter 
nuclei; nuclear division.  Consists of prophase, metaphase, anaphase, and telophase. 
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Myalgias. Muscle pain from diseases and disorders. 
Nadir.  Low blood counts. 
Necrosis.  Cell death. 
Neurons.  Nerve cell. 
Peripheral neuropathy.  Nerve damage caused by injuries, infections, metabolic 
problems and exposure to toxins. 
Prophase.  The first stage of mitosis, consisting of coiling of the chromosomes 
accompanied by migration of the two daughter centrioles toward the poles of the cell, and 
nuclear membrane breakdown. 
Radiation.  The process by which ionization displaces an electron form the 
nucleus of an atom, resulting in an unstable atom, followed by the free atom being 
accepted by another atom, thus becoming unstable. 
RNA (ribonucleic acid).  Nucleic acid that contains ribose and the bases A, G, C, 
and U.  Carries out DNA’s instructions for protein synthesis. 
Sequential chemotherapy.  Chemotherapy in which several agents are 
administered one at a time rather than concurrently to optimize dosage and increase 
patient tolerance. 
Tachypnea.  Rapid breathing. 
Telophase.  The final phase of mitosis; begins when migration of chromosomes to 
the poles of the cell has been completed and ends with the formation of two daughter 
nuclei. 
Topoisomerase.  Enzyme that unwind and wind DNA. 
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CHAPTER II 
 
 
REVIEW OF LITERATURE 
 
Introduction      
 
Cancer is a disease characterized by an abnormal regulation of cell growth 
and reproduction that has the capability of metastasizing throughout the body.  
(Brooks, Fahey, & Baldwin, 2005; Marieb & Hoehn 2007; Schneider, Dennehy, & 
Carter, 2003) A number of factors need to be considered regarding the cause for 
cancer.  External factors are preventative determinants such as tobacco, infectious 
organisms, chemicals, smoke, fumes, and radiation.  On the other hand, internal 
factors consist of inherited mutations, hormones, immune conditions, and mutations 
arising from metabolic processes, which are all influential determinants of cancer.  
(Cancer Facts & Figures, 2009)  
Cancer Incidence 
Approximately 77% of all cancers are diagnosed in persons 55 years of age 
and older, yet anyone at anytime can be susceptible to cancer.  (Cancer Facts & 
Figures, 2009) The good news is that, according to The National Cancer Institute, 
approximately 11.1 million Americans with a history of cancer were alive in 2005 
and the number of cancer survivors is steadily increasing.  According to Cancer Facts 
and Figures (2009), approximately 1,479,350 new cases of cancer are expected in the 
United States.  
Cancer is often referred and classified as benign or malignant tumors.  
Tumors are an abnormal growth of cells caused by abnormal regulation of cell 
division.  Benign tumors grow slowly and rarely cause death but are capable of 
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damaging adjacent areas.  Unlike malignant tumors, benign tumors don’t possess the 
destructive potential and are well differentiated and well organized.  (Brooks et al., 
2005; Schneider et al., 2003)   
On the other hand, malignant tumors contain cancer cells and are very 
unpredictable and unsettled in terms of organization compared to normal cells.  
These tumors consist of a widely assorted arrangement of cells, cells with loss of 
differentiation, anomalous (irregular) mitotic characteristics, increased invasiveness 
throughout the body (metastasis), and a decreased sensitivity to drug exposure.  
(Schneider et al., 2003)  Malignant tumors are commonly susceptible to 
metastasizing, where a secondary tumor from it’s original origin develops but its 
location resides in another tissue elsewhere in the body.  (Marieb & Hoehn, 2007; 
Schneider et al., 2003)  The process of metastasis arises due to the release of attached 
tumor cells from the primary tumor, allowing entry into the circulation or lymphatic 
system.  (Marieb & Hoehn, 2007; Schneider et al., 2003)   Next, the sub-endothelial 
basement membrane of the distant tissue has the tumor cells adhere to it and the 
entrance into new tissue is then permitted and proliferation and reproduction of new 
cells form in the new tissue.  Malignant tumors are also designed to pursue 
aggressive cell proliferation, affect normal tissue and eventually terminate the host 
tissue.  (Brooks et al. 2005; Schneider et al., 2003)  Malignant tumors are of a 
disproportionate form and contain considerable amounts of necrotic areas because of 
the compromised blood flow supply and lack of apoptosis.  (Schneider et al., 2003)  
The understanding of how a normal cell develops must first be established in order to 
understand how cancer develops.   
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Cell Division and Carcinogenesis 
A normal cell in the body consists of two major parts, the nucleus and the 
cytoplasm.  The nucleus is the control center where chemical reactions and 
reproduction of the cell are orchestrated.  Vast quantities of deoxyribonucleic acid 
molecules (DNA) called genes, reside in the nucleus of the cell.  Genes control the 
heredity passed on from parents to children.  (Marieb & Hoehn, 2007)  The body 
contains somatic cells that can sustain trauma, disease, or damage to the cell.  The 
body is also capable of reproducing new cells in order to replace the compromised 
cells.  In addition, there is a large amount of cell reproduction that continuously 
occurs in places like bone marrow and skin. Conversely, neurons and striated muscle 
cells either have infrequent or no reproduction of new cells. The normal cell growth 
and division consists of a cell cycle, which involves two phases, the interphase and 
cell division (mitosis or M phase).  (Schneider et al., 2003) The interphase is the 
period beginning from cell formation to cell division consisting of 90% of the cell 
cycle.  Cell division is vital to the body’s growth and repairing of tissue and in most 
body cells consists of two events, mitosis and cytokinesis.  (Marieb & Hoehn, 2007)  
Mitosis consists of a number of eloquent events where two daughter cells develop 
from the mother cell.  This goes into four phases involving the prophase, metaphase, 
anaphase, and telophase where all of the phase’s transition into the other at a 
continuous rate and the duration varies according to the type of cell.  (Marieb, & 
Hoehn, 2007)  Cytokinesis, starts at a later time during the anaphase, and is finished 
after the mitosis phase ends.  The body’s cells contain pairs of chromosomes.  Within 
these pairs of chromosomes are genes made up of DNA molecules.  These genes are 
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responsible and considered the backbone for the creation of life through sending 
messages to the chromosomes periodically instructing the body’s process of growth 
and function.  However, this isn’t always the case and unfortunately errors arise and 
pose threats to reproduction.  The body is capable of repairing some of the errors yet, 
if they occur while in the stages of cell division, the cell’s genes can be compromised 
causing mutations.  This destructive shift can ultimately cause an abnormality among 
the chromosome within the cancer cell and the cancer then starts to develop as the 
abnormal chromosome begins to reproduce.  (Schneider et al., 2003) 
Carcinogenesis, which is defined as the steps in converting a normal cell into 
a cancerous cell, is suggested to occur in two stages (initiation and promotion) with 
the branching of substages.  (Schneider et al., 2003)  The effects carcinogens have on 
the chromosomes components during the pre-initiation stage are protected.  During 
the first stage, which is the initiation phase, a carcinogen attacks a normal cell within 
the genome of the cell, and the consequential mutated cell resorts to uncontrolled cell 
division.  (Cowan & Talaro, 2009; Schneider et al., 2003)  Therefore, causing an 
alteration or destruction among the DNA molecules of the cell or inhibition and 
ultimately complete failure of the cell’s DNA repair system.  (Cowan & Talaro, 
2009; Schneider et al., 2003)  However, an accumulation of up to ten mutations may 
have to occur in order for a cell to become cancerous.  (Schneider et al., 2003)  The 
DNA mutation is expressed as soon as the division of the cell takes place and the 
second stage (promotion) is then initiated.  (Schneider et al., 2003)  Unrestrained cell 
division, along with the promotion of tumor development begins and the cell genetic 
information can be expressed or repressed.  (Cowan & Talaro, 2009; Schneider et al., 
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2003)  In the repressed state of a mutated gene, a normal function can take place but 
the potential of expression is always in consideration.  Cancer cells can reproduce at 
any pace and the formation of tumors is the result.  These tumors then form 
throughout the body’s tissues and organs where a classification for the actual cancer 
is then established.  (Schneider et al., 2003) 
Characteristics of Cancer Cells 
 There are a number of types of cancer, where tumors are named according to 
the invaded tissue or organ within the body and the level of cell differentiation.  
Specifically, there are five classes of cancer types and each has a very extensive 
background.  Carcinomas are tumors that originate in the epithelial cells (lining of all 
tissues).  (Saladin, 2010; Schneider et al., 2003)  Melanomas are malignant tumors of 
melanocytes that are commonly on the skin, but can be seen throughout the body.  
Sarcomas are solid tumors that originate in connective tissue, bone, muscle, cartilage, 
or fat.  Leukemia is a cancer of the blood or bone marrow due to abnormal white 
blood cell (leukocyte) proliferation.  (Saladin, 2010; Schneider et al., 2003)  Lastly, 
lymphomas are malignant cancers of the lymphocytes resulting in an amplification of 
lymph glands as well as other organs where the development of lymphocytes 
normally occurs.  (Saladin, 2010; Schneider et al., 2003) 
Grading and Staging of Cancer Cells 
The grading of tumors is established according to the tumor cells microscopic 
appearance.  This presents the level of undifferentiation (anaplasia) that exists within 
the cells, where the less the cells are differentiated, the more malignant the cancer.  
(Schneider et al., 2003)  There are four classes of grading starting with grade I (low-
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grade) to grade IV (highest grade) when identifying the state of a tumor cell.  A 
grade I tumor cell is identified as a tumor with cells that are well differentiated, 
resemble normal cells, are slow growing, and not very aggressive.  Grades II and III 
tumors have a moderate and poor status of differentiated cells.  Grade IV tumors are 
poorly differentiated, their cells are immature in nature, they complicate the 
pinpointing of origin location within the tissue, are fast growing, and extremely 
aggressive.  
The term TNM Staging (tumor, nodes, metastasis) in cancer research is 
widely used for clinical and pathological purposes in determining the cancer’s extent 
and progression.  (Schneider et al., 2003)  In order to determine the proper therapy 
for a cancer patient, the cancer’s anatomic status and extent must be established.  
Through the use of TNM Staging, the higher the stage, the more the progression of 
the cancer.  The TNM Stage is categorized by the following: the letter (T) represents 
the local tumors size, (N) represents the spread of the cancer to regional lymph 
nodes, and (M) represents the presence or absence of distant metastasis.  (Schneider 
et al., 2003)  According to Schneider et al. (2003), the TNM System has four stages 
recognized within it involving the following:    
• Stage I signifies a mass limited to the organ of origin, no lymph node 
involvement, and no metastasis. 
• Stage II signifies that the original tumor has spread into immediate 
surrounding tissue and there is some lymph node involvement. 
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• Stage III signifies that tumors show an extensive primary lesion with 
fixation to deeper structures, and lymph nodes exhibit malignant 
invasion. 
• Stage IV signifies that distant metastases beyond the local site of the 
primary tumor are evident.   
Table 1 below displays the staging of the tumor; it’s size, lymph node involvement, 
and whether there is metastasis.   
Table 1. Basic Staging of the TNM System (Schneider et al., 2003) 
Tumor Stage Tumor Size Lymph nodes? Metastasis 
I <2 cm None None 
II 2-5 cm No, or yes on same side None 
III >5 cm Yes on same side None 
IV Does not matter Does not matter Yes 
Breast Cancer 
Breast cancer is an uncontrolled growth of breast cells, as a result of 
mutations, or abnormal changes in the genes responsible for regulating the growth of 
cells. (Schneider et al., 2003) There are two main types of breast cancer, first, a 
ductal carcinoma, which forms in the tubes (ducts) and transports milk from the 
breast to the nipple.  The second type, lobular carcinoma, forms in the lobules of the 
breast where milk is formed.  It has been suggested that over 95% of breast cancers 
originate from the epithelial elements of the mammary gland and are 
adenocarcinomas.  (Manton, Akushevich, & Kravchenko, 2009)  In 2009, the United 
States had 192,370 new cases of breast cancer in women and 1,910 in men.  Deaths 
are projected at 40,170 females and 440 males. (Cancer Facts & Figures, 2009) 
According to Cancer Facts & Figures (2009), breast cancer with the exception of skin 
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cancers, is the most commonly diagnosed cancer among women in the United States.  
Breast cancer is ranked as the second leading cause of death among women second to 
lung cancer.  However, from 1999-2005, incidences of female breast cancer have 
declined 2.2% per year, after increasing for over two decades.  In addition, since 
1990 women under the age of 50 have shown a drop in death rates of 3.2% per year, 
and those 50 and older a drop of 2% per year.  (Cancer Facts & Figures, 2009) 
According to Cancer Facts and Figures (2009), this decrease is due to the reduction in 
the use of menopausal hormone therapy (MHT), formerly known as hormone 
replacement therapy.  This is due to the publication of results from the Women’s 
Health Initiative in 2002, which associated MHT use to the increase of breast cancer 
and heart disease.  
Risk factors for breast cancer consist of age, family or personal history 
(inherited genetic mutations in the breast), overweight or obesity after menopause, 
the use of MHT (especially combined with estrogen and progestin therapy), physical 
inactivity, smoking, and consumption of one or more alcoholic beverages per day. 
(Cancer Facts & Figures, 2009; Marieb & Hoehn, 2007; Martini & Bartholomew, 
2007; Saladin, 2010) In addition to these risk factors, there are other factors 
considered to increase the risk for breast cancer.  These involve high breast tissue 
density, high bone mineral density, biopsy-confirmed hyperplasia, and high-dose 
radiation to the chest, typically related to a medical procedure. (Saladin, 2010; 
Cancer Facts & Figures, 2009) 
 
 
	   17	  
Categories and Staging of Breast Cancer 
The detection of breast cancer is typically seen on a mammogram in an early 
abnormal state, even before the possibility of it being physically felt by the woman or 
health care professional. There are two types of mammograms that are available.  The 
first being a screening mammogram which is used to check for breast cancer in 
women who have no signs or symptoms of the disease, and second a diagnostic 
mammogram which is used to check for breast cancer after a lump or other sign or 
symptom of the disease has been found. (Saladin, 2010; www.radiologyinfo.org)  In 
the case of a large tumor, the mass may be painless to the person in benign 
conditions. (Cancer Facts & Figures, 2009) Less common symptoms involve 
continual change in the breast, such as thickening, swelling, distortion, tenderness, 
skin irritation, redness, or scaliness, or nipple abnormalities, such as ulceration, 
retraction, or spontaneous discharge. (Saladin, 2010; Cancer Facts & Figures, 2009) 
Table 2 describes the stage of breast cancer beginning with lowest, Stage 0 to the 
highest, Stage IV, and a description of each stage.  (www.breastcancer.org) 
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Table 2. Breast Cancer Stages (www.breastcancer.org) 
Stage Definition  
0 Cancer cells remain inside the breast duct, without invasion into 
normal adjacent breast tissue. 
I Cancer is 2 centimeters or less and is confined to the breast (lymph 
nodes are clear). 
IIA No tumor can be found in the breast, but cancer cells are found in 
axillary lymph nodes (the lymph nodes under the arm) OR the 
tumor measures 2 centimeters or smaller and has spread to the 
axillary lymph nodes OR the tumor is larger than 2 but no larger 
than 5 centimeters and has not spread to the axillary lymph nodes. 
IIB The tumor is larger than 2 but no larger than 5 centimeters and has 
spread to the axillary lymph nodes OR the tumor is larger than 5 
centimeters but has not spread to the axillary lymph nodes. 
IIIA No tumor is found in the breast.  Cancer is found in axillary lymph 
nodes that are sticking together or to other structures, or cancer 
may be found in lymph nodes near the breastbone OR the tumor is 
any size.  Cancer has spread to the axillary lymph nodes, which are 
sticking together or to other structures, or cancer may be found in 
lymph nodes near the breastbone. 
IIIB The tumor may be any size and has spread to the chest wall and/or 
skin of the breast AND may have spread to axillary lymph nodes 
that are clumped together or sticking to other structures, or 
inflammatory breast cancer is considered at least Stage IIIB. 
IIIC There may either be no sign of cancer in the breast or a tumor may 
be any size and may have spread to the chest wall and/or the skin of 
the breast AND the cancer has spread to lymph nodes either above 
or below the collarbone AND the cancer may have spread to 
axillary lymph nodes or to lymph nodes near the breastbone. 
IV The cancer has spread – or metastasized – to other parts of the 
body. 
Chemotherapy Treatment and Breast Cancer 
Chemotherapy, also known as anti-cancer and antineoplastics, for it’s use in 
cancer treatment began in the 1940’s with the use of nitrogen mustard therapy.  
Dougherty, Gilman, Goodman, and Lindskog (1942-1943) first established nitrogen 
mustard therapy as a cancer treatment however, there were no published studies 
because of wartime military security considerations.  Chemotherapy is designed and 
used for curing a specific cancer; controlling tumor growth; tumor shrinkage before 
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surgery or radiation therapy; and destroying cancer cells of microscopic proportion 
that may be present after the known tumor is removed by surgery (adjuvant therapy 
for preventing recurrence).  The ultimate goal is to destroy the entirety of the tumor 
cells with very little damage to the normal cells along with limiting destructive 
effects on a normal cells function.  However, it is very difficult to narrow down 
specifications among cells because of the large similarities involved with a normal 
cell and a cancer cell.   Chemotherapy’s antineoplastic effects are most distinctive 
throughout the proliferation phases of the cell cycle and these effects jeopardize the 
malignant cells growth potential.  (Schneider et al., 2003)  Therefore, due to the 
higher amount of proliferation among cancer cells versus normal cells, a higher 
percentage of cancer cells are destroyed compared to normal cells with chemotherapy 
drugs.  (Schneider et al., 2003)   
There are two major classes of antineoplastic agents with chemotherapy that 
are classified according to their structure or cell cycle activity.  They are cell cycle 
phase-specific agents and cell cycle phase-nonspecific agents.  (Barton-Burke, 
Wilkes, & Ingwerson, 2001)  Cell cycle phase-specific agents are designed to destroy 
proliferating cells that reside in only the specific phase of the cell cycle (phases G1 
through M).  (Brown, 1987)  Cell cycle phase-nonspecific agents are designed not to 
depend on the cell cycle’s phase to be active.  (Barton-Burke et al., 2001)  In 
addition, chemotherapy drugs are categorized based on their function and the cancer 
destruction process.  For this investigation, the following chemotherapy categories in 
Table 3 are the most common in breast cancer survivors at Rocky Mountain Cancer 
	   20	  
Rehabilitation Institute. (Delgin & Vallerand, 2009; Schneider et al. 2003; 
www.chemocare.com) 
 
The use of a single chemotherapy drug is effective throughout cancer 
treatment however; the usage of a mixture (cocktail) of chemotherapy drugs appears 
to be more effective.  (Schneider et al., 2003) The benefits include paramount cell 
Table 3. Chemotherapy Categories  
Alkaloids Designed to prevent cell duplication by interrupting the 
formation of chromosomes. 
 
Alkylating 
Agents 
Designed to attack all cells in a tumor, whether they are 
reproducing or not by binding with the DNA in the cells to 
prevent reproduction. 
 
Antimetabolites Designed to attack the cells during cell division.  These 
chemotherapy drugs imitate normal cell nutrients so the 
cell consumes the drug but eventually starves to death. 
 
Antitumor 
Antibiotics 
Designed to insert into strands of DNA, either breaking the 
chromosomes or inhibiting the synthesis of RNA, which 
plays an important role in synthesis within cells. 
 
Anthracyclines Designed to insert into strands of DNA, either breaking the 
chromosomes or inhibiting the synthesis of RNA, which 
plays an important role in synthesis within cells.  Forms 
free-oxygen radicals that destroy DNA and cell 
membranes. 
 
Aromatase 
Inhibitors 
Designed to synthesize estrogen during treatment for breast 
and ovarian cancer in postmenopausal women. 
 
Estrogen 
Inhibitors 
Inhibits topoisomerase and kinase, and interferes with 
DNA transcription, replication, and function to prevent 
DNA super coiling. 
 
Monoclonal 
Antibodies 
Designed to bind only to cancer cell-specific antigens and 
induce an immunological response against the target cancer 
cell. 
 
Progestin Designed to mirror progestinic effects of progesterone.   
 
Taxanes Interrupt interphase and mitosis. 
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tissue death, where the normal tissue has a higher tolerance of the drugs due to the 
lower dosage being used.  (Schneider et al., 2003)  Another benefit consists of an 
expanded realm of drug exposure to the wide assortment of resilient cells.  (Schneider 
et al., 2003)  Yet another benefit consists of a gradual decrement of development 
among cancer cells that are resilient to specific treatments during the therapy process.  
(Schneider et al., 2003)   
Single-agent chemotherapy is the use of one chemotherapy drug throughout 
the whole treatment process, while sequential single-agent chemotherapy is the use of 
one chemotherapy drug for a period, then switching to a different chemotherapy drug 
for another period, and may continue on with other drugs.  However, combination 
chemotherapy treatment uses two or more chemotherapy drugs at one time 
throughout the duration of treatment.  Waterhouse, Gelmon, Klasa, Chi, Huntsman, 
Ramsay et al. (2006) suggest that the design of combined chemotherapy drugs should 
contain the development of certain principles consisting of the following:  
1. Each agent in the combination has proven activity as a single agent. 
2. Each drug should have a different mechanism of action such that the 
combination is additive or synergistic. 
3. Toxicities, particularly those that are dose limiting, should not overlap in 
order to give the full therapeutic dose of each drug. 
4. The best schedule developed for each drug should also be used in the 
combination, optimizing the timing of each dosing and minimizing the 
time between doses. 
5. Resistance mechanisms for each drug should be non-overlapping. 
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However, combined chemotherapy is still under continual refinement in the 
adjuvant setting for breast cancer and treatments vary by the extent of the disease.  
(Waterhouse et al., 2006) In addition, there are a number of patient disease-related 
factors to consider when determining whether sequential or combination 
chemotherapy treatment is going to be used. Cardoso et al. (2009), suggest that these 
factors consist of the following in Table 4 below. 
Table 4. Factors to Consider When Choosing Single or Combination 
Chemotherapy 
Patient related 
 
Disease related 
Menopausal status Endocrine responsiveness 
Biological age and comorbidities 
(including organ dysfunction) 
HER2 status 
Performance status and adverse effects 
of prior therapy 
Disease-free interval 
Socioeconomic and psychological 
factors 
Previous therapies and response 
obtained 
Patient preference Tumor burden (defined as number 
and site of metastases) 
Available therapies in the patient’s 
country 
Need for rapid disease and/or 
symptom control 
 
A significant factor to take into consideration when making the selection of 
an appropriate therapeutic strategy in the metastatic setting is the differences in tumor 
biology.  (Telli & Carlson, 2009)  Not only has single and combination chemotherapy 
treatment been effective, but also the use of a sequential single-agent chemotherapy 
treatment has been suggested to be even more effective than combination 
chemotherapy treatment.  (Cardoso et al., 2009)  However, many studies comparing 
combination chemotherapy treatments to single-agent therapy have been limited by 
the lack of sequential treatment comparisons.  (Telli & Carlson, 2009)  Tellie & 
Carlson (2009) also suggest that in metastatic breast cancer there are many actively 
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used single-agent chemotherapeutic agents, with the majority of the data favoring an 
anthracycline- or taxane-based approach.   
According to NCCN Clinical Practice Guidelines in Oncology (2010), in the 
situation of recurrent or metastatic breast cancer, anthracyclines are considered the 
most influential chemotherapy agent in terms of efficacy in breast cancer and are 
extensively used in the adjuvant treatment of early-staged breast cancer.  Taxanes 
(Paclitaxel & Docetaxel) along with anti-metabolites are also preferred categories for 
single-agent use.  (NCCN Clinical Practice Guidelines in Oncology, 2010)  For the 
sake of this investigation, the most effective anthracycline drug suggested for 
metastatic breast cancer treatment is doxorubicin (adriamycin).  (NCCN Clinical 
Practice Guidelines in Oncology, 2010; Telli & Carlson, 2009) 
Table 5 displays the preferred single-agents and chemotherapy combinations 
in an adjuvant chemotherapy setting and for recurrent or metastatic breast cancer, 
according to NCCN Clinical Practice Guidelines in Oncology, (2010).  For the sake 
of this investigation, the chemotherapy single-agents and combinations will only 
consist of drugs used with the breast cancer survivors from RMCRI. 
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Table 5. Preferred Chemotherapy Regimens in the Adjuvant and Recurrent or 
Metastatic Breast Cancer Setting. (NCCN Clincial Practice Guidelines in 
Oncology, 2010) 
  Adjuvant Chemotherapy 
Non-Trastuzumab -TAC 
(docetaxel/doxorubicin/cyclophosphamide)                      
-Dose-dense AC 
(doxorubicin/cyclophosphamide) followed                   
by paclitaxel every 2 weeks                                                            
-AC (doxorubicin/cyclophosphamide) 
followed by weekly paclitaxel                                                                                      
-TC (docetaxel and cyclophosphamide)                                       
-AC (doxorubicin/cyclophosphamide) 
Trastuzumab 
 
-AC followed by T+ concurrent 
trastuzumab 
(doxorubicin/cyclophosphamide followed 
by paclitaxel plus trastuzumab, various 
schedules)                                                      
-TCH (docetaxel, carboplatin, trastuzumab)                                                
-AC followed by docetaxel + trastuzumab 
Other Adjuvant Regimens 
 
-AC followed by docetaxel every 3 weeks                                   
-A followed by T followed by C 
(doxorubicin followed by paclitaxel 
followed by cyclophophamide) every 2 
weekly regimen with filgrastim support 
Recurrent or Metastatic Breast Cancer 
Single Agents 
 
-Doxorubicin (Adriamycin)                                                                                  
-Paclitaxel                                                                                     
-Docetaxel                                                                                    
-Cyclophosphamide 
Agents with Bevacizumab -Paclitaxel 
Chemotherapy Combinations -AC (doxorubicin/cyclophosphamide)                                          
-AT (doxorubicin/docetaxel; 
doxorubicin/paclitaxel) 
First-Line Agents for HER2-
Positive Disease 
-Trastuzumab + paclitaxel ± carboplatin                                      
-Trastuzumab + docetaxel 
 
NCCN Clinicial Practice Guidelines in Oncology (2010) recommends 
preferred dosages with other chemotherapy drugs and regimens used.  The selection, 
administration, and modification of these regimens are far too extensive for the sake 
of this investigation and will not be discussed.  The intervention involved with each 
agent and combination for an individual is based on expected toxicities, prior 
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treatment, patient individuality, and comorbidity.  These regimens have been 
modified over time and used in an effective manner and have shown better outcomes 
for breast cancer survivors.  The following studies suggest evidence for overall 
survival, time to treatment failure, disease-free survival, and progression-free survival 
in regards to single-agent, sequential-single agent, and combination chemotherapy 
regimens used with breast cancer survivors.  
Single-Agent vs. Single-Agent Chemotherapy 
 Sparano et al. (2008) found that the estimated 5-year survival rates were 
76.9% for the group receiving paclitaxel every 3 weeks, 81.5% for the group 
receiving docetaxel every 3 weeks, and 77.6% for the group receiving weekly 
docetaxel.  In comparison to the paclitaxel every 3 weeks group, there was a 
significantly better disease-free survival in the group receiving weekly paclitaxel 
(P=0.006), and in the group receiving docetaxel every 3 weeks (P=0.02), but not in 
the group receiving weekly docetaxel (P=0.29).  Sparano et al. (2008) also found that 
the estimated overall 5-year survival rates were 86.5% for the every 3 weeks 
paclitaxel group, 89.7% for the weekly paclitaxel group, and 87.3% for the every 3 
weeks docetaxel group.  The overall survival was significantly better in the weekly 
paclitaxel group (P=0.01) compared to the every 3 weeks paclitaxel group, but not in 
the groups receiving docetaxel every 3 weeks (P=0.25) or weekly docetaxel (P=0.80).  
 Seidman et al. (2008) found that the median time to cancer progression for 
patients receiving weekly paclitaxel was prolonged by 4 months (9 vs. 5 months; 
P<0.0001), and the addition of trastuzumab to paclitaxel in patients with HER2-2-
normal breast cancer was not associated with significantly longer time to progression 
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(7 vs. 6 months; P=0.28).  The adjustment of the line of therapy for the 3-weekly to 
weekly paclitaxel showed a significant impact to the overall survival (P=0.009), but 
the addition of trastuzumab did not have a significant impact on overall survival.  
 Forbes et al. (2008) found that over a 5-year adjuvant treatment period, the 
time to recurrence was significantly lower for the arimidex group (P=0.002) 
compared to the tamoxifen group, and at the 5 year mark, the arimidex group was at a 
significantly lower risk (P=0.0001) than the tamoxifen group.  However, there were 
no differences noted in the overall survival with either group.  
 Piccart-Gebhart et al. (2006) found that disease-free survival was significantly 
greater (85.8%) with the trastuzumab group compared to (77.4%) with the 
observational (control) group (P<0.0001), and there was no significance between the 
groups regarding the overall survival.  
 Jones et al. (2005) found that the median time to progression was significantly 
longer in the docetaxel every 3 weeks group than in the paclitaxel every 3 weeks 
group (P<0.0001), and the median overall survival was significantly longer in the 
docetaxel group than in the paclitaxel group (P=0.03).  
Paridaens et al. (2000) found that progression-free survival (during and/or 
after treatment) in first-line therapy was significantly longer for doxorubicin than for 
paclitaxel (median, 7.5 months vs. 3.9 months, respectively; P=0.0001).  They also 
found that there was no significant difference in the overall survival between the two 
study arms (P=0.38), with a median survival of 18.3 months with the doxorubicin 
arm and 15.6 months with the paclitaxel arm.   
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 Chan et al. (1999) found that the median time to treatment failure was 
significantly longer in the docetaxel group (22 weeks) than in the doxorubicin group 
(18 weeks) using the Wilcoxon test (repeated measures on a single sample) (P=0.01).  
They also found that the median overall survival was similar with both treatment 
groups (docetaxel, 15 months; doxorubicin, 14 months) with no significant 
difference.  
 The single-agent versus single-agent chemotherapy studies had conflicting 
results regarding significant differences in regimen and duration.  Sparano et al. 
(2008) found that the groups who received paclitaxel and docetaxel every 3 weeks 
had a significantly longer duration of disease-free progression compared to the 
paclitaxel given weekly.  On the other hand, Seidman et al. (2008) found that 
paclitaxel given weekly was significantly better in disease-free progression compared 
to the group receiving paclitaxel every 3 weeks.  However, both studies found that 
the weekly paclitaxel group had a significantly longer overall survival period.   
Similarly, Jones et al. (2005) and Chan et al. (1999) found that docetaxel 
given every 3 weeks produced significantly longer median times to progression, but 
Jones et al. (2005) found docetaxel also had a longer overall survival and Chan et al. 
(1999) found no significant difference in overall survival.  However, Paridaens et al. 
(2000) found that doxorubicin given every 3rd week produced a significantly longer 
progression-free survival compared to the every 3rd week paclitaxel, but no 
significant differences in overall survival.  
Forbes et al. (2008) found that arimidex produced significantly less time to 
recurrence compared to tamoxifen and no significant difference in overall survival.  
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While Piccart-Gebhart et al. (2006) found that trastuzumab produced a significantly 
higher disease-free survival compared to the observational group.  Sparano et al. 
(2008), Seidman et al. (2008) and Jones et al. (2005) were the only studies that found 
a significant difference in overall survival.  
Combination vs. Combination Chemotherapy 
 Jones et al. (2006) found that there was a significant increase in disease-free 
survival with the docetaxel + cyclophosphamide group (86%) compared to the 
doxorubicin + cyclophosphamide group (80%) (P=0.01), but no significant difference 
between the groups in overall survival.  
Robert et al. (2006) found that the median progression-free survival was 
significantly longer in patients receiving trastuzumab + paclitaxel + carboplatin 
compared to the trastuzumab + paclitaxel group (P=0.005), and no statistical 
significance in overall survival rate.  
Romond et al. (2005) found that the trastuzumab + doxorubicin + 
cyclophosphamide + paclitaxel group had a greater disease-free survival (87.1%) 
compared to the control group using doxorubicin + cyclophosphamide + paclitaxel 
(75.4%).  However, there was a significantly greater overall survival with the 
trastuzumab group (62 deaths) compared to the control group (92 deaths) (P=0.01).  
 Nabholtz et al. (2003) found that the time to treatment failure was 
significantly longer with the docetaxel + doxorubicin group compared to the 
doxorubicin + cyclophosphamide group (median, 25.6 weeks vs. 23.7 weeks; 
respectively, P=0.04).  Overall survival was not different between docetaxel + 
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doxorubicin and doxorubicin + cyclophosphamide (median, 22.5 vs. 21.7 months; 
respectively).   
 Henderson et al. (2003) found that there was a significantly greater disease-
free survival rate with the paclitaxel + cyclophosphamide + doxorubicin group 
compared to the cyclophosphamide + doxorubicin group (P=0.002), and a 
significantly lower death rate for the paclitaxel group compared to the non-paclitaxel 
group (adjusted P=0.006; unadjusted P=0.009).  
Biganzoli et al. (2002) found that the median progression-free survival was 6 
months in the doxorubicin + paclitaxel and doxorubicin + cyclophosphamide arms, 
with no significant difference (P=0.65).  They also found that the median overall 
survival was 20.6 months in the doxorubicin + paclitaxel group compared with 
doxorubicin + cyclophosphamide group (20.5 months) with no significant difference 
(P=0.49).  
All of the studies found significant differences with combination versus 
combination chemotherapy except for Biganzoli et al. (2002).  Jones et al. (2006) and 
Nabholtz et al. (2003) compared 2 regimens with only 2 drugs and had docetaxel in 
their regimen.  They found significantly longer times to treatment failure, but neither 
found significant differences in overall survival.  
Robert et al. (2006), Romond et al. (2005) and Henderson et al. (2003) 
compared three combined chemotherapy drugs with only two combined 
chemotherapy drugs in their studies and all had a significantly longer disease-free 
survival period compared with the regimens consisting of only two drugs.  In 
addition Romond et al. (2005) and Henderson et al. (2003) had significantly longer 
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overall survival times with the three drug regimens compared to the two drug 
regimens with the exception of Robert et al. (2006).  Biganzoli et al. (2002) found no 
significant differences with the comparison of two drug regimens.  
Combination vs. Single-Agent Chemotherapy 
Miller et al. (2007) found that combined chemotherapy (paclitaxel + 
bevacizumab) versus single-agent chemotherapy (paclitaxel) significantly increased 
the 1-year survival rate (81.2% vs. 73.4%, P=0.01) however; the median overall 
survival was similar between the two regimens paclitaxel (26.7 months) and 
paclitaxel + bevacizumab (25.2 months) (P=0.16).  They also found that the 
combined chemotherapy significantly prolonged the progression-free survival 
compared to the single chemotherapy (P<0.001).   
Marty et al. (2005) found that there was statistical significance in overall 
survival for trastuzumab + docetaxel (P=0.03) versus docetaxel alone, and the median 
time to treatment failure was significantly greater for combined chemotherapy 
(median, 9.8 vs. 5.3 months; P=0.0001) versus single-agent chemotherapy.  
Mamounas et al. (2005) found that there was a significant reduction in the 
disease-free survival with the paclitaxel + doxorubicin + cyclophosphamide group by 
17% compared to the doxorubicin + cyclophosphamide group (P=0.006), and there 
was no significant difference between the overall survival rate.  
Citron et al. (2003) found that overall survival was significantly prolonged 
with dose-dense regimens (II and IV) (P=0.01), (II) Doxorubicin every 2 weeks for 4 
cycles followed by paclitaxel every 2 weeks for 4 cycles followed by 
cyclophosphamide every 2 weeks for 4 cycles and (IV) Doxorubicin plus 
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cyclophosphamide every 2 weeks for 4 cycles followed by paclitaxel every 2 weeks 
for 4 cycles. They also found that disease-free survival was significantly prolonged 
with dose-dense regimens (II and IV) compared with the every 3-week regimen 
(P=0.01).   
 Sledge et al. (2003) found that overall survival had no significant differences 
with median survivals of 19.1 months (doxorubicin), 22.4 months (doxorubicin + 
paclitaxel), and 22.5 months (paclitaxel).  However, the time to treatment failure was 
statistically significant with a longer median for doxorubicin + paclitaxel (8.2 
months) compared to either single-agent doxorubicin (6 months) (P=0.002) or single-
agent paclitaxel (6.3 months) (P=0.05).  
 Slamon et al. (2001) found that chemotherapy treatment (paclitaxel + 
doxorubicin + cyclophosphamide) combined with trastuzumab compared with 
chemotherapy treatment alone (paclitaxel + doxorubicin + cyclophosphamide) had a 
significantly longer time to treatment failure (median, 6.9 vs. 4.5 months; P<0.001), 
and a significantly longer median survival time 25.1 vs. 20.3 months (P=0.04).   
 There are conflicting results with the studies mentioned regarding single-
agent and sequential single-agent versus combination chemotherapy regimens.  
Sledge et al. (2003) found that single agents doxorubicin and paclitaxel compared to 
doxorubicin and paclitaxel combined show significantly longer times to treatment 
failure, but no significance in overall survival.  While Citron et al. (2003) found that 
sequential single-agent regimens given every 2 weeks show significantly longer 
overall survival and disease-free survival compared to sequential single-agent 
regimens given every 3 weeks.  
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 Mamounas et al. (2005) and Slamon et al. (2001) found that 3 or more drugs 
involved with combination regimens given every 3 weeks show significant 
improvement in disease-free survival, while Slamon et al. (2001) found results 
suggesting a significantly longer overall median survival time.  
Miller et al. (2007) and Marty et al. (2005) found that the two drug 
combination regimens significantly prolonged time to treatment failure and 
progression-free survival compared to single-agent treatment.  Miller et al. (2007) 
found a significantly longer 1-year survival rate but not overall survival with the 
combination regimen.  Marty et al. (2005) found significantly longer overall survival 
with the combination regimen.  
Among all of the studies mentioned regarding single-agent, sequential single-
agent, and combination chemotherapy treatment, the results show positive evidence 
for all treatment regimens at different times with different dosages.  It has been 
shown that the treatment seems to be most effective for single-agent, sequential 
single-agent, and combination chemotherapy treatment in 3-week intervals (Chan et 
al., 1999; Henderson et al., 2003; Jones et al., 2006; Jones et al., 2005; Mamounas et 
al., 2005; Marty et al., 2005; Nabholtz et al., 2003; Paridaens et al., 2000; Robert et 
al., 2006; Slamon et al., 2001; Sledge et al., 2003; and Sparano et al., 2008).  It has 
also been suggested that 4-week (Miller et al. 2007) and 2-week intervals (Citron et 
al. 2003), as well as weekly intervals (Seidman et al. 2008 and Sparano et al. 2008) 
have been effective.   
	   33	  
In addition to the parameters found in the previous research many others such 
as toxicities, side effects, mental impairments, and physical impairments are 
generally addressed as detrimental factors placed on the body by chemotherapy.  
Side Effects and Toxicities 
There are substantial side effects with chemotherapy and this plays a 
significant role in everyday activities.  The most common side effect with 
chemotherapy is fatigue (Byar, Berger, Bakken, & Cetak, 2006; De Jong, Courtens, 
Abu-Saad, & Schouten, 2002; Donovan, Jacobsen, Andrykowski, Winters, Balducci, 
Malik et al., 2004; Patrick, Ferketich, Fram, Harris, Hendricks, Levin et al., 2004) 
Fatigue is not a consistent symptom and may appear throughout the cancer treatment 
and even months after the treatment process.  (Wu, Dodd, & Cho, 2008)  Fatigue is a 
controversial symptom that hasn’t been fully understood in regards to the 
mechanisms.  (Wu et al., 2008)  However, studies have shown significant 
improvement in fatigue with exercise.  (Davidson et al., 2005; Hsieh, Sprod, Hydock, 
Carter, Hayward, & Schneider, 2008; Schneider, Hsieh, Sprod, Carter & Hayward, 
2007; Schwartz, Mori, Gao, Nail, & King, 2001, and Wu et al., 2008)  
Throughout the cancer therapy process whether it involves chemotherapy, 
hormonal therapy, radiation therapy, or surgery, there is extensive toxicity (side-
effects) involved.  Toxicities involved with therapy can occur in the cardiovascular, 
immune, pulmonary, gastrointestinal, musculoskeletal, neuroendocrine, and hepatic 
systems.  (Schneider, Dennehy, Roozeboom, & Carter, 2002)  Schneider et al. (2002) 
reported that radiation has acute and chronic effects on the cardiovascular systems 
involve the pericardium, myocardium, and coronary arteries.  In addition, 
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chemotherapy agents specifically doxorubicin has been shown to damage the heart by 
way of cardiomyopathies (i.e. ischemic, dilated, hypertrophic, restrictive).  
(Schneider et al., 2002)  Hematopoietic toxicity involves damage to tissues that 
produce bone marrow, leucopenia, and granulocytopenia.  (Schneider et al., 2002)  
Pulmonary toxicity symptoms involve coughing, dyspnea, low-grade fever, fatigue, 
low tolerance to exercise, restlessness, and tachypnea.  (Schneider et al., 2002)  
Abdominal radiation symptoms involved with gastrointestinal system toxicity include 
vomiting, nausea, and loss of appetite.  Chemotherapy symptoms include nausea and 
vomiting which lead to increased energy requirements, nutritional deficiency, 
dehydration, electrolyte imbalance, diarrhea, abdominal pain and intestinal disease.  
(Schneider et al., 2002)  The musculoskeletal effects with radiotherapy and 
chemotherapy consist of muscle wasting and cachexia, and tissue necrosis, while 
hepatic toxicity symptoms include rapid weight gain, increases in abdominal girth, 
fatigue, and anorexia.  (Schneider et al., 2002)  Neuroendocrine toxicities that stem 
from radiotherapy may include cell necrosis and atrophy when relating to thyroid 
tissue impairment, while chemotherapy symptoms involve anything from confusion, 
memory loss, hearing loss, and drop foot.  (Schneider et al., 2002)  Lastly, 
dermatological toxicities can consist of hair loss, specifically with chemotherapy 
drugs.  (Schneider et al., 2002)  
Exercise Training in Breast Cancer Survivors 
 
 Exercise has become increasingly important in our everyday lives and there has 
been a plethora of research in regards to its health benefits.  Exercise has been shown to 
reduce obesity, strengthen cardiovascular capacity, reduce cardiovascular disease, 
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increase lung capacity and pulmonary function, strengthen bone and muscle, reduce the 
effects of aging, increase quality of life, and other alterations.  (Brooks et al., 2005) 
Exercise programs can also benefit the cancer survivor similar to the healthy individual 
but can also improve fatigue, depression, and other debilitating side effects.  (Schneider 
et al., 2003) 
 There have been a substantial amount of studies conducted on the effects of 
exercise in breast cancer survivors who were currently undergoing chemotherapy 
treatment.  However, there is limited research investigating the effects of exercise on 
cancer survivors taking varying categories of chemotherapy drugs.  Most research has 
collectively combined all breast cancer survivors regardless of the chemotherapy 
treatment.  Therefore, the purpose of this investigation was to group survivors according 
to their chemotherapy agent and compare exercise test results among the different 
categories.  The studies in Table 6 show evidence of the effects of exercise, pre- & post- 
(aerobic & resistance training) during and/or after chemotherapy with female breast 
cancer survivors. 
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Table 6. Exercise Research and Benefits 
Study  
&  
Type 
Matthews et al. 
2007 
(Randomized 
Control Trial) 
Drouin et al.  
2006 
(RCT) 
Courneya et al.  
2003 
(RCT) 
Hutnick et al.  
2005 
(Controlled 
Clinical Trial) 
Subjects 36 21 53 36 
Age 51-57 35-65 50-69 29-69 
Treatment Chemotherapy, 
Radiation, 
Surgery,  
Combination 
Chemotherapy, 
Radiation,  
Surgery, 
Combination 
Chemotherapy, 
Radiation, 
Hormone, 
Surgery, 
Combination 
Chemotherapy,  
Radiation,  
Surgery, 
Combination 
Cancer 
Treatment 
Status 
Within last 12 
months 
Radiation 5 
d/wk for 7 wks 
12 months 
before study 
Study done 2 
wks after 
treatment 
Exercise 
Treatment 
12 wks 7 wks 15 wks 12 wks 
Assessment Baseline 
measurements 
from current 
activity levels 
Modified Bruce 
treadmill test 
Cycle 
ergometer test 
(60 rpm, 2-min 
workloads at 
30 W w/↑ of 
15 W until 
pVO2max met 
Not applicable 
Exercise 
Intervention 
1st 4 wks  
(3 times/wk, 
20-30 
min/session) 
Last 5 wks     (5 
times/wk, 30-40 
min/session) 
20-45 
min/session, 
walking & 
treadmill 
Cycle ergo, 15 
min/session for 
wks 1-3, 
ending at 35 
min/session for 
wks 13-15 
40-90 
min/session, 
aerobic & 
resistance 
exercise 
Intensity Moderate, RPE 
(11-13) 
50-70% (HRM) 70-75% 
pVO2max 
60-75% 
(HRM) 
Frequency See intervention 3-5 days/wk 3 days/wk 3 days/wk 
Results Significant 
(P=0.01) ↑in 
self-reported 
walking  
Significant 
(P<0.01)↑ in 
total walking 
time (min/wk)  
Significant 
(P<0.001) 6% 
median measure 
improvement in 
pVO2max 
w/exercise 
group 
Significant 
(P<0.001) ↑ in 
pVO2max 
w/exercise 
group  
Increase in 
VO2max & 
strength, not 
significant 
	   37	  
 
Study  
&  
Type 
Kolden et al.  
2002 
(Before & after, 
w/out control) 
Mock et al. 
2004 
(RCT) 
Mutrie et al. 
2007 
(RCT) 
Campbell et al. 
2005 
(RCT) 
 
Subjects 40 108 177 19 
Age 45-76 30-69  29-76 
 
E = 48 (± 10)  
C = 47 (± 5) 
Treatment Chemotherapy, 
Radiation, 
Hormone, 
Surgery, 
Combination 
Chemotherapy,  
Radiation,  
Surgery 
Chemotherapy,  
Radiation,  
Combination 
Chemotherapy,  
Radiation,  
Combination 
Cancer 
Treatment 
Status 
Post-surgery 58% received 
RT  
42% received 
CT  
~24 wks after 
diagnosis 
Before & 
during study 
Exercise 
Treatment 
16 wks Either 6 wks for 
RT or 12 to 24 
wks for CT 
12 wks, w/24 
wk follow-up 
12 wks 
Assessment Single-stage 
submax 
treadmill test, 
estimated 1-RM 
bench & leg 
press test 
12-minute walk 
test (Larson et 
al., 1996) 
12-minute 
walk test 
12-minute 
walk test 
(McGavin et 
al., 1976) 
Exercise 
Intervention 
60 min/session, 
Aerobic & 
resistance 
exercise 
15-minute walk 
to 30-minute 
walk over time 
45 
min/session, 
low level 
aerobics 
30 minutes 
(warm-up, 
aerobic/anaero
bic exercise, 
cool-down) 
Intensity 40-60% 
pVO2max,  
↑ to 70% by wk 
16 
~50-70% 
(HRM) 
50-75% 
(HRM) 
60-75% 
(HRM) 
Frequency 3 days/wk 5-6 times/wk 2 days/wk Unknown 
Results Significant  
(P<0.001) ↑ in 
VO2max, bench 
& leg press tests 
Significant 
(P<0.01) 
improvement in 
increased 
functional 
capacity 
Significant 
(P<0.0001) 
improvement 
in 12-minute 
walk 
Significant 
(P<0.01) 
improvement 
in 12-minute 
walk  
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Study  
&  
Type 
Pinto et al.  
2003 
(RCT) 
Segal et al. 
2001 
(RCT) 
Thorsen et al.  
2005 
(RCT) 
Turner et al.  
2004 
(RCT) 
Subjects 24 99 111 10 
Age M (52.5) M (~51) 18-50 33-63 
 
Treatment Chemotherapy, 
Radiation, 
Surgery 
Chemotherapy, 
Radiation, 
Hormonal, 
Combination 
Chemotherapy, 
Radiation, 
Surgery 
Chemotherapy,  
Radiation,  
Surgery 
Cancer 
Treatment 
Status 
Post-surgery During study Before study M (17 months 
prior to study) 
Range 4-60 
months 
 Exercise 
Treatment 
12 wks 26 wks 14 wks 8 weeks, (6 
week & 3 
month follow-
up) 
Assessment Cycle 
ergometer peak 
test (50 rpm, 
w/↑of 25 W 
every 2 minutes 
Modified 
Canadian 
Aerobic Fitness 
Test (mCAFT) 
Cycle 
ergometer, 50 
rpms. 
Submax 
bicycle 
ergometer test 
Exercise 
Intervention 
60 min/session, 
aerobic training,  
Last month, 
strength training 
Unknown 
min/session, 
progressive 
walking 
program 
30 minutes 
(walking, 
resistance 
training, 
cycling, 
aerobics, water 
activities, 
jogging) 
40-60 minutes, 
Low-impact 
aerobics, 
Resistance 
training: 2-3 
sets, 8-12 reps 
 
Intensity 60-70% (HRM) 50-60% 
pVO2max 
60-70% 
(HRM) 
Aerobic: 70-
90% (HRM) 
Resistance: 
moderate 
Frequency 3 days/wk 5 days/wk 2 times/wk 1 time/wk  
Results Significant 
(P<0.05 & .01) 
↓ in SBP, DBP; 
SBP, DBP, & 
HR at 75 W 
workload  
3% & 2% ↑ in 
pVO2max with 
SDEG & SEG 
respectively 
VO2max 
increased 23% 
in intervention 
group  
No significant 
results 
regarding 
fitness 
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Study  
&  
Type 
Nikander et al.  
2007 
(RCT) 
Hsieh et al.  
2008 
(Pre-test &  
Post-test) 
Schneider et al.  
2007 
(Pre-test &  
Post-test) 
Subjects 30 96 113 
Age 41-65 58 56  
Treatment Chemotherapy,  
Radiation,  
Endocrine, 
Combination 
Chemotherapy, 
Radiation,  
Surgery, 
Combination 
Chemotherapy,  
Radiation 
Cancer 
Treatment 
Status 
Post-treatment Complete 96 completed 
RT and/or CT 
17 during 
Exercise 
Treatment 
12 wks 24 wks 24 wks 
Assessment Figure-8 running test 
(Gillquist et al., 1986) 
Bruce treadmill test Bruce 
treadmill test  
Exercise 
Intervention 
50 min/session, aerobic 
exercise 
60 min/session, whole-
body exercise 
60 min/session, 
whole-body 
exercise 
Intensity RPE (11-16) 40-75% (HRR) 40-75% (HRR) 
Frequency 1 day/wk 2-3 days/wk 2-3 days/wk  
Results Significant (P<0.05) 
improvement in Figure-8 
running & CMJ power 
Significant  
(P<0.05) improvement 
in treadmill time & 
pVO2max 
Significant  
(P<0.05) 
improvement 
in  
treadmill time 
& pVO2max 
 
Exercise and Breast Cancer 
The studies in Table 6 show research completed on exercise and breast cancer 
survivors.  Every study involved female breast cancer survivors who had either been on 
chemotherapy or were currently receiving chemotherapy treatment before and/or during 
the study.  Additionally Table 6 shows the results of the exercise tests.  As can be seen 
other treatments were involved (i.e. radiation, surgery, hormone and endocrine therapy, 
and combinations) with these studies, along with different treatment times.  
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All of the studies in Table 6 were conducted by a randomized control trial with 
the exception of Hutnick et al. 2005 (Controlled Clinical Trial); Kolden et al. 2002 
(Before & After w/out a control); Hsieh et al. 2008 (Pre- vs. Post-test); and Schnieder et 
al. 2007 (Pre- vs. Post-test).  Hsieh et al. 2008 and Schneider et al. 2007 used a pre- 
versus post-test design, while Kolden et al. 2002 also used a pre- versus post-test design. 
Hutnick et al. 2005 used a controlled clinical trial, not randomized because the attempt of 
a blind study wasn’t applicable to their study.  
Most of the independent variables with the studies consisted of the effect on 
VO2max (Courneya et al., 2003; Drouin et al., 2006; Hsieh et al., 2008; Hutnick et al., 
2005; Kolden et al., 2002; Schnieder et al., 2007; Segal et al., 2001; Thorsen et al., 2005; 
and Turner et al., 2004).  While Matthews et al. 2007; Mock et al. 2004; Mutrie et al. 
2007; and Campbell et al. 2005 measured walking time, and Hsieh et al. 2008; and 
Schneider et al. 2007 measured treadmill time in addition to O2max and Nikander et al. 
2007 measured running & counter-movement jump (CMJ) power.   Hutnick et al. 2005 
and Kolden et al. 2002 also measured strength in addition to O2max.  Lastly, Pinto et 
al. 2003 measured systolic and diastolic blood pressure, heart rate, and rate of perceived 
exertion.   
Significant increases in O2max were found by Drouin et al. (2003), (6% 
increase, P<0.001); Courneya et al. (2003), (0.24 ml/min increase, P<0.001); Kolden et 
al. (2002), (4.62 ml/kg increase, P<0.001); Hsieh et al. (2008), (P<0.05); and Schneider et 
al. 2007, (15% increase, P<0.05); while Hutnick et al. (2005), Segal et al. (2001), and 
Thorsen et al. (2005) had increases in O2max but not significant.  Significant increases 
in meters walked were found by Mutrie et al. (2007), (3% increase, P<0.0001) and 
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Campbell et al. (2005), (+328 [± 145], P<0.01) in a 12-minute walk test, while Matthews 
et al. (2007) found significant differences in self-reported walking (P=0.01) and total 
walking time (from 103 to 134 to 147 min/week, P<0.01).  Nikander et al. (2007) found 
significant increases in Figure-8 running and counter movement jump (CMJ) (~5% and 
~10% respectively, P<0.05) and Hsieh et al. 2008 and Schneider et al. 2007 found 
significant increases in treadmill time (37.16%, 27.03%, 28.57%, 33.54% and 1.03 & 
1.30 minutes respectively, P<0.05).  Mock et al. (2004) found a significant increase in 
functional capacity (P<0.01) and Pinto et al. (2003) found significant decreases in 
baseline systolic and diastolic blood pressure (-13.55 & -8.89 respectively, P<0.05), heart 
rate (-10.78 bpm, P<0.05), and systolic and diastolic blood pressure (-36.45, P<0.01,        
-7.77, P<0.05 respectively) at a 75-watt workload.  Kolden et al. (2002) found significant 
improvement in bench and leg press (11.68 & 60.08 lbs respectively, P<0.001), while 
Hutnick et al. (2005) found improvement in muscle strength but not significant.  With the 
exception of Hutnick et al. (2005), Segal et al. (2001), Thorsen et al. (2005), and Turner 
et al. (2004), all of the studies found a significant improvement/increase in exercise pre- 
versus post-intervention.   
Summary 
 Breast cancer is the second leading cause of death for women in the U.S. 
however; death rates are declining because of modifications in chemotherapy treatment.  
Toxicities, physical and mental symptoms will continue to decline as chemotherapy 
treatment advances, along with the incorporation of exercise and a healthy diet.   Exercise 
has been found to be a vital part of the rehabilitation process for breast cancer survivors 
and will only continue to support health benefits, wellness, and quality of life.  
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CHAPTER III 
 
METHODOLOGY 
Experimental Design 
There is much research regarding the effects of chemotherapy treatment on breast 
cancer survivors.  For the sake of this investigation, research concerning specific 
chemotherapy drugs used at the Rocky Mountain Cancer Rehabilitation Institute and 
suggested evidence for results regarding overall survival; disease-free survival, 
progression-free survival, and time to treatment failure will be used.  In addition, the 
research concerns single-agent, sequential single-agent, and combination chemotherapy 
treatments involving the chemotherapy drugs used at RMCRI.  Moreover, single-agent 
and sequential single-agent will be grouped together and compared to combination 
chemotherapy treatment because of the small portion of sequential single-agent 
chemotherapy-treated breast cancer survivors who were involved with this investigation 
from RMCRI.   
The purpose of this research was to determine the differences in physiological 
parameters following an exercise intervention in breast cancer survivors on a single 
chemotherapy drug versus combination chemotherapy treatment.  A secondary purpose 
was to determine if differences exist between categories of chemotherapy drugs.  The 
data for this investigation came from the Rocky Mountain Cancer Rehabilitation Institute 
database. 
Participants 
The study was conducted on fifty-four female breast cancer survivors who had 
received either single-agent (n = 34) or combination (n = 20) chemotherapy treatment for 
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breast cancer, before, during or after their exercise intervention.  The participants were a 
convenient sample chosen from the RMRCI database that had completed specific 
physiological parameters and pre- and post-exercise assessment. Parameters collected 
were age, height, weight, blood pressure, heart rate, forced vital capacity (FVC), forced 
expiratory volume (FEV1), predicted O2max (ml/kg/min), time on treadmill, chest press, 
latissimuss dorsi pull-down, shoulder press and sit-and-reach. 
Exercise Training 
 The exercise intervention consisted of 3 to 6 months of exercise training between 
pre- and post-assessments and included 1-hour sessions, 2-3 days per week, at moderate 
intensities involving aerobic and resistance training, flexibility, range of motion, balance, 
and stretching.  Equipment used during the intervention included the Cybex Exercise 
Equipment® (chest press, lat-pull down, shoulder press), Exerstrider® walking poles, 
Quinton Q60® treadmill, NuStep, resistance machines, dumbbells, therabands, bosu 
balls, fitballs, medicine balls, wall-wheel, wall rope-pulley, dyna disks, and balance pads. 
 The equipment specifically used for the pre- and post-assessments were the 
Cybex Exercise Equipment® (chest press, lat-pull down, shoulder press), Quinton 
Medtrack ® treadmill, Spirometrics, Inc. Flowmate Plus pulmonary spirometer, sit-and-
reach scale, heart rate monitor, blood pressure cuff, stethoscope, pulse-oximeter, and a 
metronome. 
Collection of Data 
 The cardiovascular endurance test was conducted using a Bruce Treadmill 
Protocol to measure the client’s cardiorespiratory fitness.  Table 7 displays the design of 
the Bruce Treadmill Protocol VO2peak Test including the stage, speed, and grade.  The 
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test was terminated based upon the client’s volitional fatigue, whether they asked to stop, 
or the assessor’s determination for the termination.  In addition, the following is 
RMCRI’s guidelines to stop the treadmill test: 
1. ACSM’s indications for terminating exercise testing (page 106, 7th edition). 
2. Heart rate does not increase with increased intensity. 
3. Systolic blood pressure does not increase with increased intensity. 
4. Diastolic blood pressure fluctuates more than 10 mmHg from baseline. 
5. Oxygen saturation drops below 80 (pulse oximeter). 
6. Heart rate exceeds maximum heart rate using the following formula: 
HRmax = 205.8 – (0.685 x age). 
The time is recorded in the form of a decimal by dividing the seconds by 60 and 
the time does not include the warm-up. 
Table 7. Bruce Treadmill Protocol VO2peak Test 
STAGE SPEED (MPH) GRADE (%) 
Warm up 1.7 0 
1 1.7 10 
2 2.5 12 
3 3.4 14 
4 4.2 16 
5 5.0 18 
 
Pulmonary function test involved FEV1% (the amount of exhalation in the first 
second) and FVC% (the total volume of air the client can exhale), which are measured 
through a dry spirometer.  The client is instructed to exhale as forcefully as possible and 
then continue exhaling as long as possible without bending at the waist and wearing a 
nose clip to prevent any air from passing through the nose.  Two test values are obtained 
and if the second FVC% score is more than 5% higher or lower than the first FVC% 
score, the test must be repeated for a third time.  The highest value is used for both 
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FVC% and FEV1%.  The following standards (norms) are adapted from the American 
College of Sports Medicine’s (ACSM) pulmonary function prediction equations: 
 ≥ 95%   = Excellent 
 81-94% = Within normal limits (WNL) 
 75-80% = Lower limit of normal (LLN) 
 < 75%   = Low 
The weight machine protocols (chest, lat-pull down, shoulder) are listed in Table 
8 with the predetermined weight percentages for each modality. 
Table 8. Percentage of Body Weight To Be Lifted (RMCRI, 2009) 
Exercise Age: < 45 
Men       Women 
Age: 45-60 
Men      Women 
Age: 60-70 
Men      Women 
Age: > 70 
Men      Women 
Shoulder 
press 
.300           .225 .280           .210 .265           .200 .250           .185   
Lat 
Pulldown 
.500           .375 .470           .350 .440           .330 .410           .310 
Chest 
Press 
.500           .375 .470           .350 .440           .330 .410           .310 
 
The client was instructed to perform a couple of repetitions in order to establish if 
more, less, or no weight was to be adjusted.  For the weight machine tests, a metronome 
was set at 25 bpm (beats per minute).  The optimal number of repetitions was established 
between 8 and 12 and did not exceed 15.   The following exercise tests were instructed by 
the assessor to the client for each modality. 
A. Shoulder Press 
1. Adjust the seat so that when the client grasps the handles, the elbows 
are at less than or equal to a 90-degree angle. 
2. Have client sit on seat with back and buttocks against the backrest. 
3. Feet should be placed flat on the floor and shoulder-width apart. 
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4. Full repetition: 
UP: Raise training arm until arms are at near full extension. 
DOWN: Lower training arm until elbows are at a 90-degree angle. 
B. Lateral Pull-Down 
1. Have client sit on bench seat with thighs positioned comfortably 
underneath the pad. 
2. Adjust seat so client’s shoulders line up with the line on the machine. 
3. Client’s torso should remain upright throughout the lift (not leaning 
forward or backward). 
4. Full repetition: 
DOWN: Pull training arm down until elbows are at a 90-degree angle. 
UP:  Allow training arm to rise until arms are at near full extension. 
C. Chest Press 
1. Adjust the seat so the handles are at mid-chest height. 
2. Have client sit on seat with back and buttocks against backrest. 
3. Feet should be placed flat on the floor approximately shoulder-width 
apart. 
4. Full repetition: 
UP:  Press outward until arms are at near full extension. 
DOWN:  Lower training arm until elbows are at a 90-degree angle. 
D. Modified Sit and Reach Procedure 
For the modified sit and reach test, the client sits on the floor with 
shoulders, head, and buttocks against a wall and legs straight out in front.  
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A 12-inch sit and reach box was placed against the soles of the feet with 
the zero end of the yardstick toward the client.  The client held her arms 
straight forward from the shoulders toward the box, placing one hand on 
top of the other and keeping the head and shoulders against the wall.  The 
yardstick was positioned so that the zero end was touching the fingertips.  
The client bent forward, sliding the fingertips along the top of the 
yardstick.  The client’s knees did not bend and the hands stayed together.  
The inches were used at the farthest tip of the fingertips and recorded. 
Drug Treatment 
 The drugs used with the breast cancer survivors for this investigation are 
described in Table 9.   
Table 9. Chemotherapy Drugs Used With Breast Cancer Survivors at RMCRI. 
Drug Type Side Effects How it Works 
Arimidex 
(Anastrozole) 
 
 
Aromatase 
Inhibitor 
Hot flashes, 
nausea, 
decreased energy 
and weakness, 
bone pain, & 
cough 
Blocks the 
enzyme 
aromatase used 
to convert 
androgens into 
estrogen. 
Tumors 
dependent on 
this hormone 
for growth and 
will shrink 
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Avastin 
(Bevacizumab) 
Mono-
clonal 
Antibody 
Generalized 
weakness, pain, 
abdominal pain, 
nausea, vomiting, 
poor appetite, 
constipation, 
diarrhea upper 
respiratory 
infection, 
headache, hair 
loss 
Interferes with 
angiogenesis by 
targeting and 
inhibiting 
human vascular 
endothelial 
growth factor 
(VEGF). 
Carboplatin 
(Paraplatin) 
 
 
Alkylating 
Agent 
Low blood 
counts, nadir, 
nausea, vomiting, 
taste changes, 
hair loss, 
weakness, & 
blood test 
abnormalities 
Cell-cycle non-
specific (resting 
phase of the 
cell) 
Cytoxan 
(Cyclophos-
phamide, 
Neosar) 
 
 
Alkylating 
Agent 
Low blood 
counts, nadir, 
hair loss, nausea, 
vomiting, poor 
appetite, loss of 
fertility, 
discoloration of 
the skin or nails 
Cross-links 
DNA Cell-
cycle non-
specific (resting 
phase of the 
cell); inhibits 
DNA synthesis 
Doxyrubicin 
(Adriamycin, 
Rubex) 
 
 
Anthracycl
ine 
Pain on side 
where medication 
was given, low 
blood counts, 
nadir, nausea, 
vomiting, mouth 
sores, hair loss 
Non-cell-cycle 
specific 
(multiple 
phases of the 
cell), affects 
cells only when 
they are 
dividing 
Exemestane 
(Aromasin) 
Aromatase 
Inhibitor 
Fatigue, nausea, 
hot flashes, 
depression, bone 
pain, insomnia, 
anxiety, shortness 
of breath 
Blocks the 
enzyme 
aromatase used 
to convert 
androgens into 
estrogen.  
Tumors 
dependent on 
this hormone 
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Faslodex 
(Fulvestrant) 
Estrogen 
Inhibitor 
Nausea, 
vomiting, 
weakness, hot 
flashes, 
headache, bone 
pain, 
constipation, 
abdominal pain, 
diarrhea, cough 
Blocks estrogen 
(interferes with 
cell growth) 
from going into 
the cancer cell 
Femara 
(Letrozole) 
Aromatase 
Inhibitor 
Hot flashes, 
bone/back/joint 
pain, nausea, 
fatigue, shortness 
of breath, 
coughing 
Blocks the 
enzyme 
aromatase used 
to convert 
androgens into 
estrogen.  
Tumors 
dependent on 
this hormone 
Herceptin 
(Trastuzumab) 
Monoclon
al 
Antibody 
Fever, body pain, 
weakness, 
nausea, 
headache, 
shortness of 
breath 
Targets the 
HER2/neu 
receptor on 
cancer cells and 
prevents cells 
from 
multiplying 
Megace 
(Megestrol, 
Megestrol 
Acetate) 
Progestin Weight gain, 
edema, menstrual 
bleeding 
Stops hormone 
production, 
blocks hormone 
receptors 
Tamoxifen 
(Novaldex) 
Estrogen 
Inhibitor 
Hot flashes, 
vaginal 
discharge, 
swelling, loss of 
libido 
Stops hormone 
production, 
blocks hormone 
receptors; 
Interacts with 
protein kinase 
C and 
stimulation of 
human NK 
cells 
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Taxol 
(Paclitaxel, 
Onxal) 
 
Taxane Low blood 
counts, 
arthralgias & 
myalgias, hair 
loss, nausea, 
vomiting, 
diarrhea, 
hypersensitivity 
reaction 
Mitotic 
inhibitor; Cell-
cycle non-
specific (resting 
phase of the 
cell) 
Taxotere 
(Docetaxel) 
Taxane Low white & red 
blood cell count, 
nadir, nausea, 
hair loss, 
diarrhea, mouth 
sores, fatigue, 
weakness, nail 
changes, 
peripheral 
neuropathy 
Mitotic 
inhibitor; Cell-
cycle non-
specific (resting 
phase of the 
cell) 
  
Table 10 displays the single and combination chemotherapy treatment regimens 
used with the breast cancer survivors for this investigation. 
Table 10. Single & Combination Chemotherapy Treatment 
Single-Agent (n = 34) 
 
Combination (n = 20) 
Tamoxifen = 23 Adriamycin + Cytoxan = 2 
Arimidex = 8 Cytoxan + Femara = 1 
Taxol = 2 Carboplatin + Herceptin = 1 
Taxotere = 1 Cytoxan + Taxotere = 2 
 Tamoxifen + Megace = 1 
 Adriamycin + Cytoxan + Taxotere = 6 
 Adriamycin + Cytoxan + Tamoxifen = 2 
 Adriamycin + Cytoxan + Taxol = 2 
 Adriamycin + Cytoxan + Taxotere + Herceptin = 1 
 Adriamycin + Cytoxan + Taxotere + Taxol = 1 
 Adriamycin + Cytoxan + Avastin + Faslodex = 1 
 
Statistical Analyses 
The statistical analysis included the dependent variables systolic/diastolic blood 
pressure, resting heart rate, treadmill time, predicted O2max, FVC%, FEV1%, chest 
press, lat-pull down, shoulder press, and sit-and-reach for single-agent and combination 
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chemotherapy clients, pre- versus post-assessment results. Paired t-tests (unequal 
variance) were run between single and combination chemotherapy group’s participant 
characteristics and significance was established at the 95% confidence interval (P<0.05). 
The data analyses were performed with SAS 9.2 and Microsoft Excel. 
A Principle Components Analysis (PCA) was conducted to group the variables 
into appropriate components based off of a four-factored rotated factor pattern.  There 
were four variable groups used in the PCA and MANOVA including Pre- and Post-Blood 
Pressure (BP), Cardio, Oxygen, and Muscle.  Each variable group consisted of the 
appropriate physiological variables with the greatest variance among each other. The first 
principal component represents for as much of the variability in the data as possible, and 
each following component accounts for as much of the remaining variability as possible. 
A Multivariate Analysis of Variance (MANOVA) was performed to determine 
change over time for the pre- and post-assessment results between overall therapy 
category, therapy (Single vs. Combination), and drug (i.e. Taxol vs. Cytoxan + Femara) 
categories.  A MANOVA was used to find the optimal combination of the dependent 
variables and account for the variance associated with the independent variables, which 
were then separated out, and each one and interaction on the linear composite was tested.  
(Thomas, Nelson, & Silverman, 2005)  Differences were considered significant at the 
95% level of confidence (P<0.05) and obtained with the Wilks’ Lambda distribution.  
 The FACTOR Procedure Rotation Method: Varimax for the Pre- and Post-test 
data and each variable are presented in Table 14.  This statistical method was used to 
describe variability among observed variables in terms of a potentially lower number of 
unobserved variables (factors).  (Thomas et al., 2005)  
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CHAPTER IV 
 
RESULTS 
INTRODUCTION 
The purpose of this research was to determine the differences in physiological 
parameters following an exercise intervention in female breast cancer survivors on a 
single chemotherapy drug versus combination chemotherapy drugs.  A secondary 
purpose was to determine any differences in chemotherapy categories. 
Data obtained from breast cancer survivors concerning their breast cancer stage, 
chemotherapy treatment, exercise test results pre- versus post-training was compiled from 
the Rocky Mountain Cancer Rehabilitation Institute at the University of Northern 
Colorado.  These research data were used in order to answer more questions about 
exercise as a therapeutic measure for cancer survivors.  
Participant Characteristics 
 The population used in this investigation included current, past, and deceased 
breast cancer survivors who participated in the rehabilitation program at the Rocky 
Mountain Cancer Rehabilitation Institute.  The study consisted of data from fifty-four 
participants who were chosen based on completed physiological results.  A combined 
fifty-four breast cancer survivors were selected with thirty-four single-agent 
chemotherapy treated subjects and twenty combination chemotherapy treated subjects. 
Table 11 displays the participant characteristics including the mean of age (years), height 
(inches), and weight (pounds). There were no significant differences between single-
agent and combination chemotherapy treated groups with the participant’s characteristics.  
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All of the pre- and post-assessment results consisted of either three to six-month exercise 
interventions.  
Table 11. Participant Characteristics 
 Single-Agent (n = 34) 
 
Combination (n = 20) p-value 
Age (yrs.)   55.80 ±   8.75   53.48 ±   6.73 0.12 
Height (in.)    64.40 ±   2.66   63.72 ±   2.40 0.19 
Weight (lbs.)  161.92 ± 37.93 159.20 ± 30.21 0.67 
 
 Note. Values are means ± standard deviation (SD). 
Table 12 displays single-agent and combination chemotherapy categories 
associated with the chemotherapy drugs used by the breast cancer survivors.  Clients 
were categorized into one of three therapy categories.  The combination group therapy 
category 1 had anthracycline, alkylating agent, and taxane drugs.  Therapy category 2 had 
anthracycline and alkylating agent drugs.  Therapy category 3 had no required drug and 
was a combination of various drugs.  Therapy category 1 was established due to the drug 
effect that anthracyclines, alkylating agents, and taxanes have on the body’s 
physiological parameters.  Therapy category 2, unlike the first, did not involve taxanes, 
and therapy category 3 consisted of different combined chemotherapy drugs.   
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Table 12. Chemotherapy Categories For Single and Combination Treatments 
Single-Agent (n = 34)  
Drug Category = 1 
 
Combination (n = 20)  
Drug Category = 2 
 
Estrogen Inhibitor  = 23 
(Therapy Category = 1) 
Anthracycline + Alkylating Agent + Taxane = 8 
Anthracycline + Alkylating Agent + Taxane + Taxane = 1 
Anthracycline + Alkylating Agent + Taxane + 
Monoclonal Antibody = 1 
(Therapy Category = 1) 
Aromatatse Inhibitor  = 8 
(Therapy Category = 2) 
Alkylating Agent + Anthracycline = 2 
Alkylating Agent + Antrhacycline + Estrogen Inhibitor = 
2 
Alkylating Agent + Anthracycline + Estrogen Inhibitor + 
Monoclonal Antibody = 1 
(Therapy Category = 2) 
Taxane = 3 
(Therapy Category = 3) 
Alkylating Agent + Monoclonal Antibody = 1  
Alkylating Agent + Taxane = 2 
Alkylating Agent + Aromatase Inhibitor = 1 
Estrogen Inhibitor + Progestin = 1 
(Therapy Category = 3) 
 
Analysis of Data 
 Table 13 displays the physiological parameters measured for single and 
combination chemotherapy treated breast cancer survivors.  The values are presented as 
means ± SD and significance is indicated by the p-value.  Significance was found in 
single and combination groups for FVC%, FEV1%, chest press, lat pulldown, shoulder 
press, sit-and-reach, and resting heart rate (combination only).  No significant difference 
was found in systolic or diastolic blood pressures, resting heart rate for single, treadmill 
time, or predicted O2max. 
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Table 13. Physiological Parameters 
VARIABLE 
 
SINGLE (Mean)  
(n = 34) 
 
COMBINATION (Mean)  
(n = 20) 
 Pre-Test Post-Test p-value Pre-Test Post-Test p-value 
Systole  
(mm/Hg) 
124.62  
± 19 
124.24  
± 14 
0.86 124.65 
 ± 15 
122.20  
± 11 
0.27 
Diastole  
(mm/Hg) 
78.24  
± 8  
77.15  
± 8 
0.48 78.20  
± 8 
75.30  
± 9 
0.21 
Resting Heart 
Rate 
(beats/minute) 
83.53 
 ± 11  
81.60  
± 11 
0.28 94.35  
± 13 
87.75  
± 11 
0.04* 
FVC% 93.25  
± 15 
95.29  
± 14 
0.001* 96.90  
± 15 
102.56  
± 12  
0.006* 
FEV1% 83.37   
± 15 
87.24  
± 14 
0.004* 91.20  
± 15  
97.80  
± 12  
0.01* 
Treadmill  
(minutes) 
5.81   
± 2  
6.84  
± 2  
0.39 7.00  
± 2  
8.20  
± 2  
0.10 
VO2max 
(ml/kg/min) 
22.00  
± 5  
24.00  
± 5  
0.40 22.60  
± 6  
27.54  
± 7  
0.15 
Chest Press  
(reps) 
9.82  
± 6 
16.32  
± 7 
0.001* 9.85  
± 4  
16.35  
± 7  
0.006* 
Lat Pulldown  
(reps) 
14.40  
± 8  
24.10  
± 14  
0.001* 16.30  
± 11  
23.20  
± 14  
0.01* 
Shoulder Press 
(reps) 
8.10  
± 7  
17.30  
± 12  
0.001* 7.75  
± 6  
17.50  
± 8  
0.001* 
Sit-and-reach 
(inches) 
12.60  
± 4  
13.00  
± 3  
0.01* 11.64  
± 3  
12.19  
± 4  
0.04* 
 
Note. Values are means ± SD.  * = Differs significantly from pre-test values (P<0.05). 
 Figures 1 and 2 show the change in pre- to post-assessments for single and 
combination chemotherapy treatment regimens, respectively. There was a significant 
difference in RHR (combination only), FVC%, FEV%, chest press, lat pulldown, 
shoulder press, and sit-and-reach. 
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Figure 1. Single Chemotherapy (n=34) Present Change Pre- to Post-Assessment. 
 
Note. * = Significance at P<0.05. 
 
-4 
-2 
0 
2 
4 
6 
8 
10 
-0.38 
-1.09 
-1.93 
*2.04 
*3.87 
1.03 
2.00 
*6.50 
*9.70 
*9.20 
*0.40 
Pr
es
en
t C
ha
ng
e 
	   57	  
 
Figure 2. Combination Chemotherapy (n=20) Present Change Pre- to Post-Assessment. 
Note. * = Significance at P<0.05 
 
 Table 14 displays the rotated factor pattern for every variable measured.  This 
statistical method was used to describe variability among observed variables in terms of a 
potentially lower number of unobserved variables (factors).  The underlined values 
represent the variables with the greatest association between each, in each column. 
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Table 14. Rotated Factor Pattern 
VARIABLE FACTOR 1 
 
FACTOR 2 FACTOR 3 FACTOR 4 
PreBench  0.84970 -0.00762  0.07643 -0.21134 
PreLats  0.64599  0.10892  0.08537 -0.04005 
PreShoulder  0.63113  0.31693  0.03642 -0.10785 
PreSitnreach  0.49203  0.16247 -0.07899  0.04480 
PreVO2max  0.32855  0.79911  0.02827 -0.05770 
PreTreadmill  0.15472  0.79263 -0.11857 -0.16368 
PreFVC  0.04061  0.05559  0.75513 -0.02876 
PreFEV  0.20493  0.03203  0.74361  0.04948 
PreRHR -0.15299 -0.17966  0.47781  0.11978 
PreExDiastole -0.14634 -0.00207  0.17362  0.68389 
PreExSystole -0.00362 -0.36504 -0.07966  0.54577 
 
PostTreadmill  0.85954  0.05888 -0.16904  0.00725 
PostVO2max  0.84113  0.05877 -0.18282  0.03517 
PostSitnreach  0.38934 -0.06245 -0.23875 -0.09422 
PostFEV -0.01597  0.80759  0.02423 -0.01121 
PostFVC  0.14330  0.80634 -0.03871 -0.09299 
PostRHR -0.16558  0.37981  0.13591  0.33111 
PostExSystole -0.26394 -0.06570  0.78268 -0.00542 
PostExDiastole -0.19942  0.09612  0.76890 -0.03978 
PostLats  0.13001 -0.00477  0.02929  0.67625 
PostShoulder  0.02017  0.02674 -0.08226  0.61184 
PostBench -0.14660 -0.05262  0.01534  0.49665 
 
 Table 15 displays the overall means and standard deviations of the four variable 
group’s factors compared for both single and combination chemotherapy subjects.  The 
four variable group’s factors consisted of the following: 
 Blood Pressure (BP)  = Systole and Diastole 
Cardio = FVC%, FEV1%, and RHR 
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 Oxygen = Predicted O2max and Treadmill 
 Muscle = Bench, Lats, Shoulder, and Sit-and-reach 
Table 15. Means of Four Factor Groups 
N VARIABLE MEAN STD DEV 
PreBP 101.61 11.33 
PostBP   99.97 10.32 
PreCardio   89.46 14.05 
PostCardio   90.98 12.35 
PreOxygen   14.22   3.87 
PostOxygen   16.13   4.44 
PreMuscle    9.02   4.13 
54 
PostMuscle  14.02   5.39 
 
Table 16 displays the means and standard deviations for all therapy and drug 
categories for single and combination chemotherapy subjects pre- and post-assessment.  
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Table 16. Means By Therapy and Drug Category 
THERAPY 
CATEGORY 
DRUG 
CATEGORY 
N VARIABLE MEAN STD  
DEV 
 
PostBP 102.32 10.27 
PreBP 
 
102.90 12.66 
PostCardio 85.82 13.40 
PreCardio 
 
84.84 12.96 
PostOxygen 14.73 3.39 
PreOxygen 
 
13.50 3.94 
PostMuscle 14.03 5.52 
1 23 
PreMuscle 
 
9.40 4.16 
PostBP 101.12 10.62 
PreBP 
 
102.31 6.81 
PostCardio 91.83 9.07 
PreCardio 
 
91.37 14.83 
PostOxygen 14.58 4.74 
PreOxygen 
 
13.95 3.77 
PostMuscle 15.89 7.57 
2 8 
PreMuscle 
 
7.75 3.95 
PostBP 87.00 7.00 
PreBP 
 
87.66 10.26 
PostCardio 94.77 15.69 
PreCardio 
 
88.55 9.24 
PostOxygen 19.52 4.54 
PreOxygen 
 
16.59 4.15 
PostMuscle 10.16 4.81 
1 (Single) 
3 3 
PreMuscle 9.00 4.41 
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PostBP 97.35 11.00 
PreBP 
 
102.45 12.77 
PostCardio 95.90 7.76 
PreCardio 
 
91.83 16.29 
PostOxygen 19.87 4.74 
PreOxygen 
 
17.08 3.79 
PostMuscle 13.23 4.17 
1 10 
PreMuscle 
 
11.02 3.12 
PostBP 96.90 9.73 
PreBP 
 
101.70 5.78 
PostCardio 99.60 13.44 
PreCardio 
 
102.40 10.89 
PostOxygen 16.33 2.92 
PreOxygen 
 
12.87 1.40 
PostMuscle 14.04 3.83 
2 5 
PreMuscle 
 
7.30 4.18 
PostBP 103.40 6.06 
PreBP 
 
101.10 11.24 
PostCardio 92.66 11.33 
PreCardio 
 
90.53 13.94 
PostOxygen 15.37 5.41 
PreOxygen 
 
12.14 3.13 
PostMuscle 14.85 5.64 
2 (Combination) 
3 5 
PreMuscle 7.08 5.66 
 
Figure 3 displays the results from the MANOVA analyses including the overall 
therapy category (single versus combination), overall drug category (i.e. single 1 versus 
combination 1) and overall therapy category x drug category interaction.  No significant 
difference was found with any of the MANOVA analyses. 
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Figure 3. Single Versus Combination Chemotherapy MANVOA Results Pre- and Post-
Assessment. 
Summary 
The main hypothesis (H1) for this investigation was that breast cancer survivors 
receiving single-agent and sequential single-agent chemotherapy treatment would show 
significantly greater results in physiological parameters measured in pre- and post-
exercise assessments compared to breast cancer survivors receiving combination 
chemotherapy.  H1 was rejected. There were no significant differences between single or 
combination chemotherapy treatment pre- and post-assessments.  Additionally, H2 was 
rejected. There were no significant differences in the chemotherapy categories between 
single and combination chemotherapy treatment regimens.  H3 was accepted.  There were 
significant differences (P<0.05) in exercise performance with the single pre- to post-
exercise assessment and with the combination pre- to post-exercise assessment.  The 
single and combination groups showed improvements on FVC%, FEV1%, chest press, lat 
pulldown, shoulder press, sit-and-reach, and resting heart rate (combination only).   
0.56 
0.58 
0.60 
0.62 
0.64 
0.66 
0.68 
Overall Therapy 
Category 
Overall Drug 
Category 
Overall Therapy 
Category x Drug 
Category 
0.68 
0.63 
0.61 
P 
va
lu
e 
	   63	  
CHAPTER V 
 
DISCUSSION 
Effect of Exercise Training on Breast Cancer Survivors 
Many researchers have studied the impact of exercise training on breast cancer 
survivors receiving chemotherapy.  This investigation is in agreement with Pinto et al. 
(2003) concerning a significant decrease in heart rate after exercise.  Pinto et al. (2003) 
found a significant (-10.78 bpm, P<0.05) decrease in heart rate at a 75-Watt workload, 
while this study found a significant (-6.60 bpm, P<0.05) decrease in resting heart rate 
with only the combination group.  This investigation is also in agreement with Kolden et 
al. (2002) concerning a significant (+11.68 lbs, P<0.001) increase in bench press while 
this investigation found a significant (Single – change (6.50%) reps, P<0.001; 
Combination – change (6.85%) reps, P<0.006) increase in chest press repetitions.  This 
investigation is in agreement with Hutnick et al. (2005), Thorsen et al. (2005), and Segal 
et al. (2001) concerning an increase in O2max but not significantly. 
This investigation is not in agreement with Hsieh et al. (2008), Schneider et al. 
(2007), Drouin et al. (2006), Courneya et al. (2003), and Kolden et al. (2002) concerning 
a significant increase in predicted O2max or treadmill time (Hsieh et al. 2008 & 
Schneider et al. 2007).  This investigation is not in agreement with Pinto et al. (2003) 
concerning a significant decrease in systolic and diastolic blood pressure.  
However, no research was found in relation to the purpose of this investigation 
and whether or not the effect of a single chemotherapy drug regimen versus a 
combination chemotherapy drug regimen is more or less effective in response to exercise 
tests.  This study examined the impact single versus combination chemotherapy regimens 
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have on physiological parameters involved with exercise.  There were significant 
differences (P<0.05) found between pre- and post-assessments within the single and 
combination chemotherapy treatment regimens for pulmonary tests FVC% and FEV1%, 
chest press, lat pulldown, shoulder press, sit-and-reach, and resting heart rate 
(combination only).  These findings suggest a beneficial impact exercise has on 
physiological parameters measured with breast cancer survivors who have received either 
single or combination chemotherapy treatment.  These findings also suggest the 
similarities between the specific parameters found to be significant with both 
chemotherapy treated subjects.   
Effect of Single and Combination Chemotherapy Drugs 
 No significant difference was seen between single and combination chemotherapy 
drugs.  However, the significant differences found pre- to post-assessment were similar 
between single and combination chemotherapy treatment regimens therefore; the 
physiological changes were similar between therapy categories pre- to post-assessment.  
The following studies found significant differences with breast cancer survivors and 
exercise treatment before, during, and after treatment.   
 Thorsen et al. (2005), Turner et al. (2004), and Courneya et al. (2003) conducted 
their studies before treatment and found no significant differences, but Courneya et al. 
(2003) found significant (P<0.001) difference in O2max. 
 Schneider et al. (2007) and Campbell et al. (2005) conducted their studies before 
and during treatment and Schneider et al. (2007) found significant difference in treadmill 
time and O2max (P<0.05) and Campbell et al. (2005) in 12-minute walk (P<0.01). 
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 Mutrie et al. (2007), Drouin et al. (2006), Mock et al. (2004), and Segal et al. 
(2001) conducted their studies during treatment.  All but Segal et al. (2001) found 
significant differences in (12-minute walk, P<0.0001; O2max, P<0.001; and Functional 
capacity, P<0.01), respectively. 
Hsieh et al. (2008), Matthews et al. (2007), Nikander et al. (2007), Hutnick et al. 
(2005), Pinto et al. (2003), and Kolden et al. (2002) conducted their studies after 
treatment.  All but Hutnick et al. (2005) found significant differences in (Treadmill time 
& O2max, P<0.05; Self-reported walking, P=0.01, Total walking time, P<0.01; Figure-
8 running & CMJ power, P<0.05; Systolic/Diastolic blood pressure, P<0.05, Heart rate, 
P<0.01; and O2max, bench & leg press, P<0.001), respectively. 
The findings of these investigations suggest that an exercise intervention can 
produce a significant improvement at any time throughout the chemotherapy treatment 
process.  However, no research has been found suggesting significant difference between 
single chemotherapy and combination chemotherapy treatment.  The findings of no 
significance between therapy categories with this investigation may suggest that the 
physiological side effects of chemotherapy are similar between therapy categories and 
that no one therapy category has more impact on physiological parameters involved with 
exercise. 
Effect of Chemotherapy Drug Categories 
 Although slight improvements were found, there were no findings of significant 
differences (P=0.63) between chemotherapy drug categories single versus combination 
with this investigation.  Physiologically, the aforementioned studies suggest exercise 
treatment can be found significant at any point in the chemotherapy treatment process.  
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However, with this investigation, whether any chemotherapy drug(s) existed in the breast 
cancer survivor at the time of the pre- and post-assessment, and if any side effects had 
any impact on the breast cancer survivor’s exercise performance, and whether significant 
difference could have been found, remains unclear.  There has been no research found 
concerning chemotherapy drug categories and exercise training with breast cancer 
survivors and any interaction between each treatment.   
Effect of Interaction Between Drug Therapy and Drug Category 
 Similarly, even though slight improvements were found, there were no findings of 
significant differences (P=0.61) between the interaction of single therapy and drug 
categories with combination therapy and drug categories with this investigation.  Again, 
this may suggest whether the existence of chemotherapy drug(s) the breast cancer 
survivor was on may or may not have had an impact with any physiological side effects 
and influence on the assessments and intervention.  Also, there has been no research 
found concerning therapy interaction with chemotherapy drug categories and exercise. 
Summary and Conclusions 
 The findings of this investigation indicate there is a significant benefit in an 
exercise intervention program for breast cancer survivors who have received either single 
or combination chemotherapy regimens from a pre- to a post-assessment.  The findings 
also suggest that both single and combination chemotherapy are similar in terms of the 
impact an exercise intervention has on either treatment concerning the physiological 
parameter’s measured (FEV1%, FVC%, heart rate (combination only), chest press, lat 
pulldown, shoulder press, sit-and-reach).  In addition, the findings raise the question of 
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whether one chemotherapy treatment is more effective than the other and specific 
research concerning drugs and categories would be valuable. 
Future Study 
 Further research should be performed specifically concerning chemotherapy 
treatment times and encompassing all possible chemotherapy drugs, categories and 
combination regimens.  In addition, a larger sample size of breast cancer survivors all 
starting their exercise intervention and pre- and post-assessments at the same time and 
narrowing down the individualized exercise prescriptions to be as close to each breast 
cancer survivor as possible should be implemented.  Further research should concentrate 
on the physiological parameters of major muscle groups, treadmill times, pulmonary 
function tests, blood pressure, heart rate, flexibility, and psychological parameters 
(fatigue, depression, motivation).  
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